Eli Lilly and Co (LLY) Position Decreased by James Investment Research Inc.

James Investment Research Inc. reduced its position in shares of Eli Lilly and Co (NYSE:LLY) by 72.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,619 shares of the company’s stock after selling 6,740 shares during the period. James Investment Research Inc.’s holdings in Eli Lilly and were worth $220,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LLY. Tarbox Group Inc. increased its position in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the period. First Citizens Bank & Trust Co. increased its position in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock valued at $476,000 after buying an additional 18 shares during the period. Enterprise Financial Services Corp increased its position in shares of Eli Lilly and by 0.9% in the third quarter. Enterprise Financial Services Corp now owns 2,150 shares of the company’s stock valued at $173,000 after buying an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in shares of Eli Lilly and by 0.7% in the third quarter. Jackson Grant Investment Advisers Inc. now owns 3,931 shares of the company’s stock valued at $316,000 after buying an additional 26 shares during the period. Finally, Accredited Investors Inc. increased its position in shares of Eli Lilly and by 1.0% in the third quarter. Accredited Investors Inc. now owns 3,257 shares of the company’s stock valued at $261,000 after buying an additional 32 shares during the period. Institutional investors own 75.15% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and Co (NYSE:LLY) traded up 0.29% during midday trading on Friday, reaching $78.53. 814,702 shares of the company’s stock traded hands. The firm’s 50-day moving average is $82.44 and its 200 day moving average is $78.16. Eli Lilly and Co has a 52-week low of $64.18 and a 52-week high of $86.72. The firm has a market cap of $82.95 billion, a PE ratio of 37.97 and a beta of 0.30. Eli Lilly and also saw some unusual options trading activity on Tuesday. Stock traders purchased 15,956 put options on the company. This is an increase of approximately 743% compared to the average volume of 1,893 put options.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. The company had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.22 billion. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. Eli Lilly and’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.83 earnings per share. Equities research analysts expect that Eli Lilly and Co will post $4.12 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Monday, May 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.66%. The ex-dividend date is Thursday, May 11th. Eli Lilly and’s dividend payout ratio is presently 80.62%.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/james-investment-research-inc-sells-6740-shares-of-eli-lilly-and-co-lly-updated.html.

Several brokerages recently weighed in on LLY. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. BMO Capital Markets set a $71.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, April 25th. Goldman Sachs Group Inc reissued a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a research note on Tuesday. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $87.00 price target on shares of Eli Lilly and in a research report on Wednesday, April 19th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $97.00 price target (up previously from $95.00) on shares of Eli Lilly and in a research report on Saturday, March 11th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $87.56.

In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of the stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the transaction, the senior vice president now directly owns 114,217 shares in the company, valued at approximately $9,452,598.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the transaction, the insider now owns 124,690,804 shares in the company, valued at $10,557,570,374.68. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply